Innova Captab Ltd
Incorporated in January 2005, Innova Captab Ltd is a pharmaceutical company is an integrated pharmaceutical company in India with a presence across the pharmaceutical value chain.[1]
- Market Cap ₹ 5,810 Cr.
- Current Price ₹ 1,015
- High / Low ₹ 1,059 / 421
- Stock P/E 67.3
- Book Value ₹ 135
- Dividend Yield 0.00 %
- ROCE 14.8 %
- ROE 14.0 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 7.53 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Part of BSE Allcap BSE SmallCap BSE IPO BSE Healthcare
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|
373 | 411 | 785 | 859 | 865 | 902 | |
322 | 356 | 687 | 760 | 755 | 786 | |
Operating Profit | 51 | 54 | 99 | 99 | 110 | 116 |
OPM % | 14% | 13% | 13% | 11% | 13% | 13% |
1 | 1 | 3 | 9 | 9 | 17 | |
Interest | 5 | 4 | 5 | 18 | 14 | 4 |
Depreciation | 10 | 6 | 7 | 11 | 11 | 12 |
Profit before tax | 38 | 46 | 89 | 78 | 94 | 116 |
Tax % | 26% | 26% | 25% | 26% | 27% | |
28 | 34 | 66 | 58 | 68 | 86 | |
EPS in Rs | 232.42 | 287.50 | 551.50 | 11.99 | 11.91 | 15.09 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 28% |
TTM: | 3% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 26% |
TTM: | 45% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 21% |
Last Year: | 14% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|
Equity Capital | 12 | 12 | 12 | 48 | 57 | 57 |
Reserves | 98 | 133 | 199 | 220 | 666 | 714 |
54 | 45 | 176 | 237 | 244 | 258 | |
81 | 178 | 157 | 173 | 187 | 218 | |
Total Liabilities | 245 | 368 | 544 | 678 | 1,155 | 1,248 |
73 | 79 | 161 | 161 | 164 | 161 | |
CWIP | 0 | 7 | 0 | 22 | 339 | 452 |
Investments | 0 | 0 | 60 | 60 | 60 | 60 |
172 | 282 | 322 | 435 | 593 | 575 | |
Total Assets | 245 | 368 | 544 | 678 | 1,155 | 1,248 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
31 | 42 | 58 | 39 | 112 | |
-6 | -20 | -188 | -88 | -472 | |
-23 | -19 | 125 | 51 | 368 | |
Net Cash Flow | 1 | 3 | -5 | 3 | 8 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Debtor Days | 85 | 123 | 81 | 98 | 92 |
Inventory Days | 84 | 107 | 63 | 67 | 68 |
Days Payable | 92 | 132 | 84 | 102 | 111 |
Cash Conversion Cycle | 77 | 99 | 60 | 63 | 49 |
Working Capital Days | 80 | 73 | 74 | 87 | 72 |
ROCE % | 28% | 33% | 21% | 15% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
7h - Of Schedule of Analyst / Institutional Investor meetings under the SEBI (LODR), Regulations 2015.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
14 Nov - Transcript of Q2 FY25 earnings call released.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
12 Nov - The officials of the Company will be attending the Investor Conference as per the below details: 1. 18th November, 2024 at 10:00 A.M - 02:00 …
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
12 Nov - Read with Schedule III (Part A) of SEBI (LODR), Regulations 2015, we would like to inform you that the officials of the Company will be …
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
11 Nov - Monitoring Agency Report for IPO proceeds utilization.
Concalls
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT
-
Jun 2024Transcript PPT REC
-
May 2024TranscriptNotesPPT
-
Feb 2024Transcript PPT
About the company[1] Sharon is engaged in the business of manufacturing intermediates, API, and formulations. It offers contract manufacturing services for pharmaceutical products and made sales worth 192 Crs.